Wisconsin Seeks Drug Testing for Medicaid
The Trump administration has indicated it is open to providing states more flexibility with Medicaid, and Wisconsin is looking to push the limits. The state may become the first to implement mandatory drug screening, testing, and treatment for anyone seeking Medicaid, reported The Boston Globe. The drug testing would be a requirement for not only Medicaid, but also food stamps and unemployment benefits. Individuals who refuse to be screened or drug tested would not be eligible to receive benefits. Those who test positive must undergo treatment or they would not receive benefits for 6 months.
Centene Will Continue Participating in ACA Exchanges
While some insurers have struggled on the Affordable Care Act (ACA) insurance exchanges and scaled back participation, Centene is committed to the exchanges. The AP reported that Centene’s exchange enrollment increased 74% since 2016 and that 80% of the 2016 exchange customers renewed their plans with Centene in 2017. Despite uncertainty around the future of the ACA’s cost-sharing assistance, Centene plans to continue selling plans in 12 states.
Moderates Not on Board With GOP Health Plan Compromise
The Conservative House Freedom Caucus may have come around on the latest compromise for the Republican healthcare bill, but many moderates have not, despite one of their own drafting the amendment. According to The Washington Post, Representative Charlie Dent, R-Pennsylvania, a leader of the GOP House moderates, does not believe the compromise addresses concerns that the bill would cut Medicaid too much. However, he, and others, have not seen legislative details for the latest version of the bill.
Eye Changes After Cataract Surgery Associated With Diabetic Retinopathy
December 11th 2023Patients receiving uncomplicated phacoemulsification surgery for cataracts had greater increases in macular and choroidal thickness if they had early diabetic retinopathy without preoperative diabetic macular edema.
Read More
Results Show Strong Responses for Brentuximab Vedotin Plus Nivolumab Combo in Patients With cHL
December 11th 2023Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).
Read More
ICYMI: Highlights From the ACCC Fall National Oncology Conference
December 11th 2023This year’s top content from the fall meeting of the Association of Community Cancer Centers (ACCC) highlights both treatment gains made through innovative referral, screening, and assistance initiatives and the ongoing need to improve health equity and research inclusivity.
Read More